VYGR - Voyager Therapeutics

-

$undefined

N/A

(N/A)

Voyager Therapeutics NASDAQ:VYGR Voyager Therapeutics is a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases. Voyager is committed to advancing the field of AAV gene therapy through innovation and investment in vector engineering and optimization, manufacturing, and dosing and delivery techniques. Voyager's wholly owned and partnered pipeline focuses on severe neurological diseases for which effective new therapies are needed, including Parkinson's disease, Huntington's disease, Friedreich's ataxia, and other severe neurological diseases.

Location: 75 Sidney St, Massachusetts, 02139-4134, US | Website: www.voyagertherapeutics.com | Industry: Biological Product (except Diagnostic) Manufacturing | Sector: Manufacturing


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

-31.39M

Cash

266.7M

Avg Qtr Burn

-3.828M

Short % of Float

6.66%

Insider Ownership

16.60%

Institutional Own.

63.44%

Qtr Updated

12/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
AAV Capsids (Pfizer) Details
Neurological disorder

Phase 1

Update

AAV Capsids (Novartis) Details
Cardiovascular disease , Neurological disorder

Phase 1

Initiation

AAV Capsids Details
Cardiovascular disease , Neurological disorder

Phase 1

Initiation

Phase 1

Initiation

Phase 1a

Data readout

GBA1 gene therapy program Details
Parkinson's disease, Central nervous system illness

IND

Submission

VY-AADC (NBIb-1817) Details
Parkinson's disease, Central nervous system illness

Failed

Discontinued

VY9323 (SOD1 silencing gene therapy) Details
Neurodegenerative disease, Amyotrophic lateral sclerosis

Failed

Discontinued

VY-HTT01 Details
Huntington's disease

Failed

Discontinued